{"created":"2024-12-12T01:57:30.081973+00:00","id":2009635,"links":{},"metadata":{"_buckets":{"deposit":"632ef288-a2d7-4bdc-89cd-23be64527d85"},"_deposit":{"created_by":7,"id":"2009635","owners":[7],"pid":{"revision_id":0,"type":"depid","value":"2009635"},"status":"published"},"_oai":{"id":"oai:tokushima-u.repo.nii.ac.jp:02009635","sets":["1713853213384:1713853295607"]},"author_link":["185"],"control_number":"2009635","item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-01-28","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageStart":"130","bibliographicVolumeNumber":"5","bibliographic_titles":[{"bibliographic_title":"International Journal of Endocrinology and Diabetes","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Glucagon-Like Peptide 1 receptor agonist (GLP-1RA) have been recently effective for diabetes. Among them, subcutaneous injection and oral form of semaglutide (Rybelsus) are in focus, in which the latter has been examined in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) studies. Rybelsus could been invented for absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, due to 30-year process of innovation by Novo Nordisk. It shows clinical effects for diabetes and obesity. For PIONEER 9 and 10 trials, efficacy and safety were shown for 3, 7 or 14 mg of Rybelsus equivalent to subcutaneous liraglutide and subcutaneous dulaglutide for 52 weeks.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Pubtexto Publishers","subitem_publisher_language":"en"}]},"item_10001_rights_15":{"attribute_name":"権利情報","attribute_value_mlt":[{"subitem_rights":"This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","subitem_rights_language":"en"}]},"item_10001_source_id_9":{"attribute_name":"収録物ID","attribute_value_mlt":[{"subitem_source_identifier":"26943875","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1715043197608":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access"}]},"item_1722929371688":{"attribute_name":"出版社版DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_language":"ja","subitem_relation_name_text":"10.36266/IJED/130"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.36266/IJED/130","subitem_relation_type_select":"DOI"}}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"板東, 浩","creatorNameLang":"ja"},{"creatorName":"バンドウ, ヒロシ","creatorNameLang":"ja-Kana"},{"creatorName":"Bando, Hiroshi","creatorNameLang":"en"}],"familyNames":[{"familyName":"板東","familyNameLang":"ja"},{"familyName":"バンドウ","familyNameLang":"ja-Kana"},{"familyName":"Bando","familyNameLang":"en"}],"givenNames":[{"givenName":"浩","givenNameLang":"ja"},{"givenName":"ヒロシ","givenNameLang":"ja-Kana"},{"givenName":"Hiroshi","givenNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"185","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"60228690","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://nrid.nii.ac.jp/ja/search/?qm=60228690"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2022-02-15"}],"displaytype":"detail","filename":"ijed_5_1_130.pdf","filesize":[{"value":"162 KB"}],"format":"application/pdf","licensetype":"license_0","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://tokushima-u.repo.nii.ac.jp/record/2009635/files/ijed_5_1_130.pdf"},"version_id":"4ae72a83-20f1-46d1-ac53-97c87f8e93bb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"semaglutide","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Rybelsus","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Peptide InnOvatioN  for  Early  diabEtes  tReatment  (PIONEER)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Novo Nordisk","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Effective oral formulation of semaglutide (Rybelsus) for diabetes and obesity due to absorption enhancer development","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Effective oral formulation of semaglutide (Rybelsus) for diabetes and obesity due to absorption enhancer development","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"7","path":["1713853295607"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-02-15"},"publish_date":"2022-02-15","publish_status":"0","recid":"2009635","relation_version_is_last":true,"title":["Effective oral formulation of semaglutide (Rybelsus) for diabetes and obesity due to absorption enhancer development"],"weko_creator_id":"7","weko_shared_id":-1},"updated":"2025-01-29T06:00:37.648119+00:00"}